- Home
- EXTR vs HRMY Comparison
EXTR vs HRMY Comparison
Compare EXTR & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXTR
- HRMY
- Stock Information
- Founded
- EXTR 1996
- HRMY 2017
- Country
- EXTR United States
- HRMY United States
- Employees
- EXTR N/A
- HRMY N/A
- Industry
- EXTR Telecommunications Equipment
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- EXTR Telecommunications
- HRMY Health Care
- Exchange
- EXTR Nasdaq
- HRMY Nasdaq
- Market Cap
- EXTR 2.2B
- HRMY 2.0B
- IPO Year
- EXTR 1999
- HRMY 2020
- Fundamental
- Price
- EXTR $17.95
- HRMY $31.70
- Analyst Decision
- EXTR Strong Buy
- HRMY Strong Buy
- Analyst Count
- EXTR 7
- HRMY 9
- Target Price
- EXTR $18.57
- HRMY $54.22
- AVG Volume (30 Days)
- EXTR 1.1M
- HRMY 627.2K
- Earning Date
- EXTR 08-06-2025
- HRMY 08-05-2025
- Dividend Yield
- EXTR N/A
- HRMY N/A
- EPS Growth
- EXTR N/A
- HRMY 13.13
- EPS
- EXTR N/A
- HRMY 2.62
- Revenue
- EXTR $1,089,717,000.00
- HRMY $744,852,000.00
- Revenue This Year
- EXTR $3.47
- HRMY $20.10
- Revenue Next Year
- EXTR $7.79
- HRMY $18.01
- P/E Ratio
- EXTR N/A
- HRMY $12.13
- Revenue Growth
- EXTR N/A
- HRMY 20.62
- 52 Week Low
- EXTR $10.10
- HRMY $26.47
- 52 Week High
- EXTR $19.24
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- EXTR 69.75
- HRMY 38.57
- Support Level
- EXTR $17.59
- HRMY $31.25
- Resistance Level
- EXTR $18.14
- HRMY $32.46
- Average True Range (ATR)
- EXTR 0.45
- HRMY 1.00
- MACD
- EXTR 0.06
- HRMY -0.37
- Stochastic Oscillator
- EXTR 89.73
- HRMY 11.69
About EXTR Extreme Networks Inc.
Extreme Networks Inc provides cloud networking solutions and industry services and support. Extreme designs, develops, and manufactures wired, wireless, and software-defined wide area-network (SD- WAN) infrastructure equipment, software and cloud-based network management solutions. The company's cloud solution is a single platform that offers unified network management of wireless access points, switches, and SD-WAN. The company operates in a single segment which develops and markets network infrastructure equipment. Roughly half of the firm's revenue is generated in the Americas, with the rest coming from Europe, the Middle East, Africa, and Asia-Pacific.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.